Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Efficiency, Safety and Portability of Gene Therapy Drug Neovasculgen (DNA Encoding the 165-amino-acid Isoform of Human Vascular Endothelial Growth Factor (pCMV - VEGF165) for Peripheral Arterial Disease Complex Treatment

NCT03068585 is registered in ClinicalTrials.gov with Artgen Biotech as lead sponsor.

NCT NCT03068585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03068585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Efficiency, Safety and Portability of Gene Therapy Drug Neovasculgen (DNA Encoding the 165-amino-acid Isoform of Human Vascular Endothelial Growth Factor (pCMV - VEGF165) for Peripheral Arterial Disease Complex Treatment
Lead sponsor
Artgen Biotech
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2010
Completion date
July 1, 2011
Enrollment
100 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial disease